Citations

Clear

40 citation(s) found for "Hall, Matthew".

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Venneti, Sriram , Kawakibi, Abed Rahman , Ji, Sunjong , Waszak, Sebastian M. , Sweha, Stefan R. , Mota, Mateus , Pun, Matthew , Deogharkar, Akash , Chung, Chan , Tarapore, Rohinton S. , Ramage, Samuel , Chi, Andrew , Wen, Patrick Y. , Arrillaga‐Romany, Isabel , Batchelor, Tracy T. , Butowski, Nicholas , Shonka, Nicole , Hall, Matthew D. , Daghistani, Doured , Beccaria, Kévin , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Kachman, Maureen , Baum, Heidi , Burant, Charles , Mottl, Sophie L. , Cartaxo, Rodrigo T. , John, Vishal , Messinger, Dana , Peterson, Erik , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R. , Wahl, Daniel , Lyssiotis, Costas A. , Nava, Daniel de la , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V. , Cain, Jason E. , Jiang, Li , Agar, Nathalie Y.R. , Zhao, Lili , Mody, Rajen , Kurokawa, Ryo , Yadav, Viveka Nand , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Nazarian, Javad , Allen, Joshua E. , Odia, Yazmín , Butowski, Nicholas A , Sumrall, Ashley , Shonka, Nicole , Harrison, Rebecca A , de Groot, John , Mehta, Minesh P , Hall, Matthew D , Daghistani, Doured , Cloughesy, Timothy F , Ellingson, Benjamin M , Beccaria, Kevin , Varlet, Pascale , Kim, Michelle M , Umemura, Yoshie , Garton, Hugh , Franson, Andrea , Schwartz, Jonathan , Jain, Rajan , Kachman, Maureen , Baum, Heidi , Burant, Charles F , Mottl, Sophie L , Cartaxo, Rodrigo T , John, Vishal , Messinger, Dana , Qin, Tingting , Peterson, Erik , Sajjakulnukit, Peter , Ravi, Karthik , Waugh, Alyssa , Walling, Dustin , Ding, Yujie , Xia, Ziyun , Schwendeman, Anna , Hawes, Debra , Yang, Fusheng , Judkins, Alexander R , Wahl, Daniel , Lyssiotis, Costas A , de la Nava, Daniel , Alonso, Marta M , Eze, Augustine , Spitzer, Jasper , Schmidt, Susanne V , Duchatel, Ryan J , Dun, Matthew D , Cain, Jason E , Jiang, Li , Stopka, Sylwia A , Baquer, Gerard , Regan, Michael S , Filbin, Mariella G , Agar, Nathalie Y R , Zhao, Lili , Kumar-Sinha, Chandan , Mody, Rajen , Chinnaiyan, Arul , Kurokawa, Ryo , Pratt, Drew , Yadav, Viveka N , Grill, Jacques , Kline, Cassie , Mueller, Sabine , Resnick, Adam , Nazarian, Javad , Allen, Joshua E , Odia, Yazmin , Gardner, Sharon L , Koschmann, Carl , Tarapore, Rohinton S , Ji, Sunjong , Wen, Patrick Yung , Arrillaga‐Romany, Isabel , Sumrall, Ashley , Groot, John de , Mehta, Minesh P. , Cloughesy, Timothy F. , Ellingson, Benjamin M. , Kim, Michelle M. , Jain, Rajan , Stopka, Sylwia A. , Baquer, Gerard , Regan, Michael S. , Koschmann, Carl

Mayo Clinic

Cancer Discovery | August 16, 2023 | Volume: 13 | Issue: 11 | Pages: 2370-2393

10.1158/2159-8290.cd-23-0131 | PMID 37584601 Get It

Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293
Systematic Identification of Copositivity Groups in Standard Series Patch Testing Through Hierarchical Clustering
Yang, Yul W. , Yiannias, James A. , Voss, Molly M., Hall, Matthew R., Youssef, Molly J. , Davis, Mark D.P. , Voelker, Dayne , Klanderman, Molly , Mangold, Aaron R. , Voelker, Dayne H, Klanderman, Molly C, Mangold, A R

Mayo Clinic

JAMA Dermatology | August 2, 2023 | Volume: 159 | Issue: 9 | Pages: 945

10.1001/jamadermatol.2023.2352 | PMID 37531132 Get It

ImportancePatients are frequently copositive for multiple allergens simultaneously, either due to chemical similarity or simultaneous sensitization. A better understanding of copositivity groups would help guide contact avoidance.ObjectiveTo use patient data to systematically determine copositivity groups in the Mayo Clinic Standard Series.Design, Setting, and ParticipantsIn this retrospective cross-sectional analysis, the Mayo Clinic patch test database was queried for pairwise copositivity rates in the 80 allergen Mayo Clinic Standard Series between 2012 and 2021. Data were collected from 3 tertiary care sites of the Mayo Clinic Contact Dermatitis Group and a total of 5943 patients were included, comprising all patients undergoing patch testing to the Mayo Clinic Standard Series allergens.Main Outcomes and MeasuresCopositivity rates between every 2 allergens in the 80-allergen Mayo Clinic Standard Series were estimated. After background correction, copositivity rates were analyzed using unsupervised hierarchical clustering to systematically identify copositivity groups in an unbiased manner.ResultsOverall, 394 921 total patches were applied to 5943 patients (4164 [70.1%] women, 1776 [29.9%] men, with a mean [SD] age of 52.3 [18.8] years ), comprising 9545 positive reactions. After background correction based on overall positivity rates, hierarchical clustering revealed distinct copositivity groups. Many were supported by prior literature, including formaldehyde releasers, cobalt-nickel-potassium dichromate, acrylates, 3-dimethylaminopropylamine-amidoamine-oleamidopropyl dimethylamine, alkyl glucosides, budesonide-hydrocortisone-17-butyrate, certain fragrances, compositae-sesquiterpene lactone mix, mercapto mix-mercaptobenzothiazole, carba mix-thiuram mix, and disperse orange-p-phenylenediamine. However, novel associations were also found, including glutaraldehyde-sorbitan sesquioleate, benzalkonium chloride-neomycin-bacitracin, bronopol-methylchloroisothiazolinone-methylisothiazolinone, and benzoic acid-iodopropynyl butylcarbamate.Conclusions and RelevanceThis retrospective cross-sectional analysis found that copositivity rates varied between allergens; allergens with extremely high positivity rates demonstrated nonspecific copositivity to multiple other allergens. Background correction based on positivity rates followed by hierarchical clustering confirmed prior known copositivity groups, contaminants and/or excipients leading to copositivity, and novel associations to guide contact avoidance.
Trends in Patch Testing with the Mayo Clinic Standard Series, 2017–2021
Zawawi, Suha, Yang, Yul W. , Drage, Lisa A., Youssef, Molly J. , Yiannias, James A. , Davis, Mark D.P. , Hall, Matthew R. , Cantwell, Hafsa M. , Hall, Matthew R

Mayo Clinic

Dermatitis® | May 16, 2023 | Volume: 34 | Issue: 5 | Pages: 405-412

10.1089/derm.2023.0063 | PMID 37192467 Get It

Background: Patch testing to a standard series is used to identify culprit allergens in patients with contact dermatitis. The reaction rates evolve over time based on trends in cutaneous exposures by the general population. Objective: The aim of this study was to analyze the patch test results of the Mayo Clinic standard series in patients tested from 2017 to 2021. Methods: The patch test reactions of standard series allergens tested from 2017 to 2021 were retrospectively reviewed and compared with the results of our prior report from 2011 to 2015 as well as the North American Contact Dermatitis Group (NACDG) report from 2017 to 2018. Results: Of 2667 patients tested, 1683 (63.1%) had at least 1 positive reaction. The 15 allergens with the highest reaction rates were hydroperoxides of linalool 1%, nickel (II) sulfate hexahydrate, methylisothiazolinone, Myroxylon pereirae resin, hydroperoxides of linalool 0.5%, methyldibromo glutaronitrile, neomycin sulfate, cobalt (II) chloride hexahydrate, fragrance mix I, benzalkonium chloride, bacitracin, hydroperoxides of limonene, methylchloroisothiazolinone/methylisothiazolinone, p-phenylenediamine, and textile dye mix. Twelve (80%) of these allergens were also in the top 15 of the most recent NACDG report. Conclusions: Hydroperoxides of linalool and hydroperoxides of limonene are new allergens that have been added to our standard series. These are associated with high reaction rates.
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 | PMID 37180971 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Trends in Patch Testing of Black Patients: The Mayo Clinic Decade Experience (January 1, 2011, to December 31, 2020)
Ajayi, Ayodeji, Hall, Matthew J. , Yiannias, James A. , Killian, Jill M. , Davis, Mark D.P. , Youssef, Molly J. , Drage, Lisa A., Cantwell, Hafsa M. , Sokumbi, Olayemi , Hall, Matthew

Mayo Clinic

Dermatitis® | January 26, 2023 | Volume: 34 | Issue: 2 | Pages: 113-119

10.1089/derm.2022.29000.aaj | PMID 36917521 Get It

Abstract: Background: Trends in patch testing for allergic contact dermatitis (ACD) have not been well characterized in Black patients. Despite similar incidence of ACD in Black and White patients, there are differences in allergen profiles. Understanding patch testing trends in Black patients furthers knowledge that has considerable impact on the management of ACD in the Black population. Objective: The purpose of this study was to review the results of patch testing in Black patients at Mayo Clinic over a decade. Methods: We retrospectively reviewed the results of patch testing to the standard, extended standard, or hairdresser series in 149 Black patients seen at Mayo Clinic (Rochester, MN; Scottsdale, AZ; and Jacksonville, FL) from January 1, 2011, to December 31, 2020. Results: During the 10-year period, 149 Black patients (mean age, 49.2 years [SD, 17.1 years]; female 67.1%) were patch tested at Mayo Clinic to the standard, extended standard, or hairdresser series. Most common sites of dermatitis were generalized (30.9%), hands (18.8%), leg (16.8%), trunk (16.1%), and arm (14.8%). Overall, 109 patients (73.2%) had at least 1 positive reaction and 74 patients (50%) had 2 or more positive reactions. Overall, the 10 allergens with the highest reaction rates (from highest to lowest) identified in our study population were 4-amino-2-hyroxytoluene (33.3%), thimerosal (20.4%), nickel sulfate (18.9%), methylisothiazolinone (16.5%), methyldibromo glutaronitrile (13.4%), methyldibromo glutaronitrile/phenoxyethanol (12.5%), captan (12.5%), carmine (12.5%), methylchloroisothiazolinone/methylisothiazolinone (11.5%), and hydroperoxide of linalool 1% (11.3%). Conclusions: We describe patch test results in Black patients over a decade at Mayo Clinic. The top 10 allergens were preservatives, hair dyes, and fragrances. Differing patterns of allergens may occur in Black patients due to different patterns of exposures related to cultural practices.
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers
Casaletto, Kaitlin B. , Kornack, John, VandeBunte, Anna M. , Staffaroni, Adam S., Lee, Shannon, Heuer, Hilary W. , Forsberg, Leah K. , Ramos, Eliana Marisa , Kramer, Joel H. , Yaffe, Kristine , Petrucelli, Leonard , Boxer, Adam L. , Rosen, Howard J. , Apostolova, Liana G. , Barmada, Sami J. , Bordelon, Yvette , Brushaber, Danielle , Coppola, Giovanni, Darby, Ryan, Domoto-Reilly, Kimiko, Faber, Kelley, Fagan, Anne M. , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Gavrilova, Ralitza, Graff-Radford, Jonathon, Graff‐Radford, Neill R. , Grant, Ian , Grossman, Murray, Hall, Matthew , Huey, Edward D. , Kauer, Daniel, Kornak, John , Lago, Argentina Lario , Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diana E., Mackenzie, Ian R. , Masdeux, Joseph C., McGinnis, Scott, Mendez, Mario F. , Mester, Carly , Onyike, Chiadi U. , Pascual, María Belén, Rademakers, Rosa , Rao, Meghana , Rascovsky, Katya, Rankin, Katherine P. , Ritter, Aaron, Savica, Rodolfo , Syrjanen, Jeremy A. , Staffaroni, Adam M. , Taylor, Jack C. , Weıntraub, Sandra , Damme, Philip Van , Van Damme, Philip , Barmada, Sami , Paolillo, Emily W. , Rojas, Julio C. , Miller, Bruce L. , Boeve, Bradley F. , Gendron, Tania F. , Appleby, Brian S. , Botha, Hugo , Bozoki, Andrea C , Clark, David , Coppola, Giovanni, Dickerson, Bradford Clark , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Goldman, Jill , Galasko, Douglas , Huang, Eric J. , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Kantarci, Kejal , Kerwin, Diana , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Pressman, Peter, Ramanan, Vijay K. , Seeley, William W. , Tartaglia, Maria Carmela , VandeVrede, Lawren , Wong, Bonnie

Mayo Clinic

JAMA Neurology | November 14, 2022 | Volume: 80 | Issue: 1 | Pages: 82

10.1001/jamaneurol.2022.4178 | PMID 36374516 Get It

ImportancePhysical activity is associated with cognitive health, even in autosomal dominant forms of dementia. Higher physical activity is associated with slowed cognitive and functional declines over time in adults carrying autosomal dominant variants for frontotemporal lobar degeneration (FTLD), but whether axonal degeneration is a potential neuroprotective target of physical activity in individuals with FTLD is unknown.ObjectiveTo examine the association between physical activity and longitudinal neurofilament light chain (NfL) trajectories in individuals with autosomal dominant forms of FTLD.Design, Setting, and ParticipantsThis cohort study included individuals from the ALLFTD Consortium, which recruited patients from sites in the US and Canada. Symptomatic and asymptomatic adults with pathogenic variants in one of 3 common genes associated with FTLD (GRN, C9orf72, or MAPT) who reported baseline physical activity levels and completed annual blood draws were assessed annually for up to 4 years. Genotype, clinical measures, and blood draws were collected between December 2014 and June 2019; data were analyzed from August 2021 to January 2022. Associations between reported baseline physical activity and longitudinal plasma NfL changes were assessed using generalized linear mixed-effects models adjusting for baseline age, sex, education, functional severity, and motor symptoms.ExposuresBaseline physical activity levels reported via the Physical Activity Scale for the Elderly. To estimate effect sizes, marginal means were calculated at 3 levels of physical activity: 1 SD above the mean represented high physical activity, 0 SD represented average physical activity, and 1 SD below the mean represented low physical activity.Main Outcomes and MeasuresAnnual plasma NfL concentrations were measured with single-molecule array technology.ResultsOf 160 included FTLD variant carriers, 84 (52.5%) were female, and the mean (SD) age was 50.7 (14.7) years. A total of 51 (31.8%) were symptomatic, and 77 carried the C9orf72 variant; 39, GRN variant; and 44, MAPT variant. Higher baseline physical activity was associated with slower NfL trajectories over time. On average, NfL increased 45.8% (95% CI, 22.5 to 73.7) over 4 years in variant carriers. Variant carriers with high physical activity demonstrated 14.0% (95% CI, −22.7 to −4.3) slower NfL increases compared with those with average physical activity and 30% (95% CI, −52.2 to −8.8) slower NfL increases compared with those with low physical activity. Within genotype, C9orf72 and MAPT carriers with high physical activity evidenced 18% to 21% (95% CI, −43.4 to −7.2) attenuation in NfL, while the association between physical activity and NfL trajectory was not statistically significant in GRN carriers. Activities associated with higher cardiorespiratory and cognitive demands (sports, housework, and yardwork) were most strongly correlated with slower NfL trajectories (vs walking and strength training).Conclusions and RelevanceIn this study, higher reported physical activity was associated with slower progression of an axonal degeneration marker in individuals with autosomal dominant FTLD. Physical activity may serve as a primary prevention target in FTLD.
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Ho, Gwo‐Yaw , Kyran, Elizabeth L. , Bedő, Justin , Wakefield, Matthew J. , Ennis, Darren , Mirza, Hasan , Vandenberg, Cassandra J. , Lieschke, Elizabeth , Farrell, Andrew , Hadla, Anthony , Lim, Ratana , Dall, Genevieve , Vince, James E. , Kondrashova, Olga , Bailey, Ulla‐Maja , Dowson, Suzanne , Bryson, Gareth , Partnership, for the Scottish Genomes, Cooke, Susanna L. , Ratnayake, Gayanie , McNally, Orla , Study12,13, for the Australian Ovarian Cancer, Weroha, S. John , Bowtell, David D.L. , McNeish, Iain A. , Scott, Clare L. , Barker, Holly E. , Ennis, Darren P , Mirza, Hasan B , Chua, Ngee Kiat , Kondrashova, Olga , Upstill-Goddard, Rosanna , Bailey, Ulla-Maja , Dowson, Suzanne , Roxburgh, Patricia , Glasspool, Rosalind , Bryson, Gareth , Biankin, Andrew V , Cooke, Susanna L , Ratnayake, Gayanie , McNally, Orla , Traficante, Nadia , Fazio, Anna de , Weroha, S John , Bowtell, David D , McNeish, Iain A , Papenfuss, Anthony T , Scott, Clare L , Barker, Holly E , Ho, Gwo-Yaw , Wakefield, Matthew J , Glasspool, Rosalind , Biankin, Andrew V. , Partnership, for the Scottish Genomes, Traficante, Nadia , Study12,13, for the Australian Ovarian Cancer, DeFazio, Anna

Mayo Clinic

Cancer Research | October 7, 2022 | Volume: 82 | Issue: 23 | Pages: 4457-4473

10.1158/0008-5472.can-21-4012 | PMID 36206301 Get It

Abstract Ovarian carcinosarcoma (OCS) is an aggressive and rare tumor type with limited treatment options. OCS is hypothesized to develop via the combination theory, with a single progenitor resulting in carcinomatous and sarcomatous components, or alternatively via the conversion theory, with the sarcomatous component developing from the carcinomatous component through epithelial-to-mesenchymal transition (EMT). In this study, we analyzed DNA variants from isolated carcinoma and sarcoma components to show that OCS from 18 women is monoclonal. RNA sequencing indicated that the carcinoma components were more mesenchymal when compared with pure epithelial ovarian carcinomas, supporting the conversion theory and suggesting that EMT is important in the formation of these tumors. Preclinical OCS models were used to test the efficacy of microtubule-targeting drugs, including eribulin, which has previously been shown to reverse EMT characteristics in breast cancers and induce differentiation in sarcomas. Vinorelbine and eribulin more effectively inhibited OCS growth than standard-of-care platinum-based chemotherapy, and treatment with eribulin reduced mesenchymal characteristics and N-MYC expression in OCS patient-derived xenografts. Eribulin treatment resulted in an accumulation of intracellular cholesterol in OCS cells, which triggered a downregulation of the mevalonate pathway and prevented further cholesterol biosynthesis. Finally, eribulin increased expression of genes related to immune activation and increased the intratumoral accumulation of CD8+ T cells, supporting exploration of immunotherapy combinations in the clinic. Together, these data indicate that EMT plays a key role in OCS tumorigenesis and support the conversion theory for OCS histogenesis. Targeting EMT using eribulin could help improve OCS patient outcomes. Significance: Genomic analyses and preclinical models of ovarian carcinosarcoma support the conversion theory for disease development and indicate that microtubule inhibitors could be used to suppress EMT and stimulate antitumor immunity.
Reevaluating Corticosteroid Classification Models in Patient Patch Testing
Chen, Joyce Y., Yiannias, James A. , Hall, Matthew R., Youssef, Molly J. , Drage, Lisa A., Davis, Mark D.P. , Yang, Yul W.

Mayo Clinic

JAMA Dermatology | September 28, 2022 | Volume: 158 | Issue: 11 | Pages: 1279

10.1001/jamadermatol.2022.3774 | PMID 36169950 Get It

Importance Individuals with allergic contact dermatitis to one topical corticosteroid may also react to other corticosteroids. Corticosteroid classification models have been proposed to predict such copositivity, recommend representative screening corticosteroids, and guide allergen avoidance. Objective To use patient data to determine copositivity patterns between corticosteroids and evaluate against previous corticosteroid classification models. Design, Setting, and Participants This qualitative study included a retrospective analysis of the Mayo Clinic Contact Dermatitis Group corticosteroid patch test data from 2010 to 2019. Among patients undergoing patch testing with the Mayo Clinic’s standard or steroid series who consented to research participation, 5637 patients were included in the analysis. Copositivity rates were determined between corticosteroids and analyzed by hierarchical clustering for comparison to previous classification models. Main Outcomes and Measures The frequency of patch test positivity to each of the analyzed corticosteroids was noted and compared with previously published patch test positivity rates. Copositivity rates between each pair of corticosteroids were determined, and overall copositivity patterns were analyzed and evaluated against known steroid classes. Results A total of 49 472 individual patches were applied to 5637 patients, testing 18 corticosteroids. Patch test positivity rates ranged between 0.3% and 4.7%. The fluocinonide positivity rate corresponded to the highest copositivity rate with other corticosteroids (mean [SD], 50.7% [26.1%]). Tixocortol-21-pivalate, 0.1%, and tixocortol-21-pivalate, 1%, positivity rates corresponded to the lowest copositivity rates (mean [SD], 4.1% [1.7%] and 3.6% [1.4%], respectively). Hierarchical clustering elucidated patterns that did not support previous corticosteroid classification models. Conclusions and Relevance In this qualitative study, copositivity rates were variable between corticosteroids, and overall patch test positivity for allergy to topical corticosteroids was rare. Previously published corticosteroid classifications are not supported by real patient-derived data and may not be accurate in predicting corticosteroid copositivity.
Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy
Tarapore, Rohinton S. , Allen, Jeffrey, McGovern, Susan L. , Zaky, Wafik , Odia, Yazmín , Daghistani, Doured , Hall, Matthew D. , Khatib, Ziad, Cantor, Evan , Kurokawa, Ryo , MacDonald, Tobey J. , Aguilera, Dolly , Vitanza, Nicholas A. , Kline, Cassie , Lu, Guangrong , Allen, Joshua E. , Khatua, Soumen , Tarapore, Rohinton S , Koschmann, Carl , Khatua, Soumen , Hall, Matthew D , Kurokawa, Ryo , Odia, Yazmin , Gardner, Sharon L , Allen, Jeffrey C. , Allen, Jeffrey, Diaz, Zuanel , Koschmann, Carl , Mueller, Sabine C.

Mayo Clinic

Neuro-Oncology Advances | September 13, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac143 | PMID 36382108 Get It

Abstract Background ONC201, a dopamine receptor D2 (DRD2) antagonist and caseinolytic protease P (ClpP) agonist, has induced durable tumor regressions in adults with recurrent H3 K27M-mutant glioma. We report results from the first phase I pediatric clinical trial of ONC201. Methods This open-label, multi-center clinical trial (NCT03416530) of ONC201 for pediatric H3 K27M-mutant diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG) employed a dose-escalation and dose-expansion design. The primary endpoint was the recommended phase II dose (RP2D). A standard 3 + 3 dose escalation design was implemented. The target dose was the previously established adult RP2D (625 mg), scaled by body weight. Twenty-two pediatric patients with DMG/DIPG were treated following radiation; prior lines of systemic therapy in addition to radiation were permitted providing sufficient time had elapsed prior to study treatment. Results The RP2D of orally administered ONC201 in this pediatric population was determined to be the adult RP2D (625 mg), scaled by body weight; no dose-limiting toxicities (DLT) occurred. The most frequent treatment-emergent Grade 1-2 AEs were headache, nausea, vomiting, dizziness and increase in alanine aminotransferase. Pharmacokinetics were determined following the first dose: T1/2, 8.4 h; Tmax, 2.1 h; Cmax, 2.3 µg/mL; AUC0-tlast, 16.4 hµg/mL. Median duration of treatment was 20.6 weeks (range 5.1-129). Five (22.7%) patients, all of whom initiated ONC201 following radiation and prior to recurrence, were alive at 2 years from diagnosis. Conclusions The adult 625 mg weekly RP2D of ONC201 scaled by body weight was well tolerated. Further investigation of ONC201 for DMG/DIPG is warranted.
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
Bajorek, Lynn, Kiekhofer, Rachel, Hall, Matthew J. , Taylor, Joanne, Lucente, Diane , Brushaber, Danielle , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Forsberg, Leah K. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan, Grant, Ian , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Toga, Arthur W. , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Hall, Matthew, Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.050692 Get It

AbstractBackgroundUp to 30% of frontotemporal dementia (FTD) cases are due to known pathogenic mutations (f‐FTD). Little is known about the factors that predict who will choose to learn their results. Upcoming clinical trials in f‐FTD may require disclosure prior to enrollment, even before symptom onset, and thus characterizing this sample is important. Furthermore, understanding the mood impacts of genetic disclosure may guide genetic counseling practice.MethodF‐FTD participants (n=568) from families with a known pathogenic mutation (MAPT, C9orf72, GRN) were enrolled through the ARTFL/LEFFTDS Longitudinal FTD Study (ALLFTD) and provided the opportunity for disclosure. Independent‐sample t‐tests compared demographic and psychosocial factors between participants who did and did not receive their results. In participants who were asymptomatic at baseline and follow up (n=199,177 with follow‐up), linear mixed effects modeling was used to investigate pre‐ to post‐disclosure changes in the 15‐item Geriatric Depression Scale (GDS).ResultOf participants from families with a known pathogenic genetic mutation, 47% received genetic disclosure. Of the asymptomatic subset (n=386), 36% know their mutation status. Of these asymptomatic learners, 46% received disclosure through the study, and the remainder learned their genetic status prior to study enrollment. None of the analyzed demographic or psychosocial factors (i.e., sex, age, education, having children) differed between learners and non‐learners (p’s > 0.05). In the longitudinal analysis of asymptomatic participants, learners showed a pre‐ to post‐increase of 0.31 GDS points/year (95%CI: ‐0.08, 0.69, p = 0.12), whereas non‐learners showed a slight decline (‐0.15 points/year, 95%CI: ‐0.36, 0.06, p = 0.16). This difference between slopes was statistically significant (0.46, 95%CI: 0.02, 0.89, p=0.04) but represents a small clinical effect. In asymptomatic learners, slopes did not differ based on mutation status (0.28, 95%CI: ‐0.66, 1.20, p=0.55). Conclusions were based on the estimates and full range of confidence intervals.ConclusionThe majority of asymptomatic research participants do not know their genetic status, which will be a consideration for clinical trials that require disclosure. No considered demographic factors were strongly associated with the decision to receive disclosure. The findings suggest that disclosure in asymptomatic participants has minimal impact on depressive symptoms regardless of genetic results.